Is Repligen (RGEN) A Smart Long-Term Buy?

Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” third-quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 1.94% was recorded by the fund for the third quarter of 2021, beating its Benchmark, the MSCI All Country World Small Cap Index, which returned -1.42 % for the same period. You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.

Harding Loevner Global Small Companies Equity Fund, in its Q3 2021 investor letter, mentioned Repligen Corporation (NASDAQ: RGEN) and discussed its stance on the firm. Repligen Corporation is a Waltham, Massachusetts-based bioprocessing company with a $14.5 billion market capitalization. RGEN delivered a 37.18% return since the beginning of the year, while its 12-month returns are up by 39.58%. The stock closed at $262.88 per share on December 03, 2021.

Here is what Harding Loevner Global Small Companies Equity Fund has to say about Repligen Corporation  in its Q3 2021 investor letter:

“Bioprocessing technology company Repligen was the largest relative contributor in the quarter. The company reported a remarkable 86% topline revenue growth for Q2, benefiting from COVID-19 vaccine and drug development-related demand. Repligen is doubling its capacity to meet its customers’ rapidly expanding bioprocessing needs.”

Pressmaster/Shutterstock.com

Based on our calculations, Repligen Corporation (NASDAQ: RGEN) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. RGEN was in 35 hedge fund portfolios at the end of the third quarter of 2021. Repligen Corporation (NASDAQ: RGEN) delivered a -10.10% return in the past 3 months.

Disclosure: None. This article is originally published at Insider Monkey.